Article History
Accepted: 18 April 2019
First Online: 17 June 2019
Competing interests
: D.A. has received grants and personal fees (consulting, advisory board fees, travel fees and grants) from Alnylam Pharmaceuticals and personal fees (advisory board fees and travel fees) from Pfizer. H.K. has received personal fees (consulting fees and travel fees) from Pfizer. M.S. has received grants and personal fees (consulting fees, advisory board fees, travel fees and grants) from Alnylam Pharmaceuticals and personal fees (advisory board fees and travel fees) from Pfizer. T.C. has received financial support to attend scientific meetings and honoraria for lectures from Alnylam, Biogen, Glaxo, Ionis and Pfizer.